A Phase 4 interventional study of Aflibercept (Eylea, BAY86-5321) in Central Retinal Vein Occlusion, sponsored by Bayer. Completed at 42 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-08.
Sponsored by Bayer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing aflibercept in Retinal Vein Occlusion — none open to participants now, none under way, none of them phase 3. aflibercept · Retinal Vein Occlusion.
Among the 21 studies testing aflibercept in Retinal Vein Occlusion, this one is the 6th largest by enrollment, is the only one that started in 2016, is one of 10 in phase 4, and was the 13th registered.
289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.
Browse Retinal Vein Occlusion studies →None of the 21 studies testing aflibercept in Retinal Vein Occlusion is open now. The open studies under Retinal Vein Occlusion, anywhere →
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 4 · Phase 4 10
First in 2009; this study’s year is marked. 1 started in 2016.
This study's enrollment of 162 is above the median of 51 across 208 interventional studies indexed under Retinal Vein Occlusion.
Median enrollment 56 across the 21 interventional studies. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 21 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Bayer has 9 studies filed under Retinal Vein Occlusion — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing aflibercept in Retinal Vein Occlusion, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Central retinal vein occlusion (CRVO) occurs when the main blood vessel that transports blood away from the retina (the very back portion of the eye) becomes blocked, causing the leakage of fluid into the retina and thereby causing a swelling of the macula (the portion of the retina responsible for fine vision). This swelling is called macular edema. When the macula swells with fluid, central vision becomes blurry. The study drug aflibercept has been shown to reduce the amount of fluid and blood leaked into the retina. It can help to stabilize, and in many cases, improve the vision loss related to CRVO. Aflibercept has been approved for the treatment of macular edema secondary to CRVO in the United States (US), European Union (EU), Japan, and other countries.
The study was considered research because, although the study drug was already on the market for macular edema secondary to CRVO, there were no studies available that addressed the questions of what were useful intervals for treating and assessing patients, how did they differ among patients, and how were criteria applied for retreatment. The purpose of this study was to evaluate the effectiveness, treatment interval, and safety of the treatment regimen (pattern for administering treatment) in subjects with macular edema secondary to CRVO. In addition, this study explored new imaging methods for assessing the affected eye.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with macular edema secondary to CRVO were treated with the study drug intravitreal aflibercept
Drug: Aflibercept (Eylea, BAY86-5321)
The recommended dose for intravitreal aflibercept was 2 mg equivalent to 50 μL. Study treatment was administered at baseline and at monthly intervals until stabilization of disease. When stability was achieved, the treatment interval could be extended based on visual and anatomic outcomes as judged by the treating investigator.
The Proportion of Participants Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) on the Early Treatment Diabetic Retinopathy Score (ETDRS) Chart Compared to Baseline
Participants who completed the study with a gain of ≥ 15 letters or dropped the study after Week 24 and having a permanent resolution of macular edema and a gain of ≥ 15 letters from baseline with regard to the latest BCVA assessment. The ETDRS chart includes 70 letters in total, more letters read correctly represents a better visual acuity.
Time frame: Baseline, Week 24 and Week 76
The Proportion of Participants With a Mean Treatment Interval Between Injections of ≥ 8 Weeks
Participants who completed the study with a mean treatment interval between injections of ≥ 8 weeks or dropped out of the study after Week 24 and having a permanent resolution of macular edema
Time frame: From the last actual visit of the initiation phase to Week 76
The Mean Treatment Interval Between Injections
Time frame: From baseline to Week 76
The Change in Best Corrected Visual Acuity (BCVA) as Measured by the Early Treatment Diabetic Retinopathy Letter Score (ETDRS) From Baseline
The ETDRS chart includes 70 letters in total and the letter score ranges from 0 to 100. More letters read correctly results in a higher letter score, which represents better visual acuity
Time frame: Baseline and Week 24, 52, and 76
The Change in Central Retinal Thickness (CRT) From Baseline
CRT was measured in the study eye by spectral domain optical coherence tomography (SD-OCT).
Time frame: Baseline and Week 24, 52 and 76
The Number of Injections Per Participant
Time frame: From baseline to Week 76
The Proportion of Participants Who Gain ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) on the Early Treatment Diabetic Retinopathy Score (ETDRS) Chart Compared to Baseline
The ETDRS chart includes 70 letters in total. More letters read correctly represents a better visual acuity
Time frame: Baseline and Week 24, Week 52
The Proportion of Participants With Change in Retinal Non-perfusion (FA/FP) Status From Baseline
The change in retinal non-perfusion status by fundus angiography (FA)/fundus photography (FP)-confirmed ischemic disc area. The status was categorized into: no non-perfusion, \<10 ischemic disc area, \>=10 ischemic disc area and missing status
Time frame: Baseline and Week 24, 52 and 76
The Proportion of Participants With Absence of Subretinal Fluid
Time frame: Baseline, week 24, week 52 and week 76
Incidence and Severity of Ocular Treatment-emergent Adverse Events
Time frame: Up to 30 days after week 76
A total of 244 participants were screened in 42 study centers in 8 countries, the first subject first visit was on 10/Jun/2016 and last subject last visit was on 31/Jun/2019
| Milestone | Intravitreal (IVT) Aflibercept |
|---|---|
| Started | 162 |
| Completed | 137 |
| Not completed | 25 |
| Withdrew: Death | 3 |
| Withdrew: Other | 10 |
| Withdrew: Physician decision | 2 |
| Withdrew: Adverse event | 6 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Lost to follow-up | 1 |
| weeks | Intravitreal (IVT) Aflibercept |
|---|---|
| The Mean Treatment Interval Between Injections | 6.37 ± 1.150 |
Participants who completed the study with a gain of ≥ 15 letters or dropped the study after Week 24 and having a permanent resolution of macular edema and a gain of ≥ 15 letters from baseline with regard to the latest BCVA assessment. The ETDRS chart includes 70 letters in total, more letters read correctly represents a better visual acuity.
| percent | Intravitreal (IVT) Aflibercept |
|---|---|
| The Proportion of Participants Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) on the Early Treatment Diabetic Retinopathy Score (ETDRS) Chart Compared to Baseline | 65.6 ± 57.7 |
Participants who completed the study with a mean treatment interval between injections of ≥ 8 weeks or dropped out of the study after Week 24 and having a permanent resolution of macular edema
| percent | Intravitreal (IVT) Aflibercept |
|---|---|
| The Proportion of Participants With a Mean Treatment Interval Between Injections of ≥ 8 Weeks | 45.0 ± 37.1 |
The ETDRS chart includes 70 letters in total and the letter score ranges from 0 to 100. More letters read correctly results in a higher letter score, which represents better visual acuity
| scores | Intravitreal (IVT) Aflibercept |
|---|---|
| Absolute BCVA letter score at baseline | 51.9 ± 16.8 |
| Absolute BCVA letter score at Week 24 | 72.4 ± 16.6 |
| Absolute BCVA letter score at Week 52 | 71.8 ± 18.1 |
| Absolute BCVA letter score at Week 76 | 72.3 ± 18.5 |
| Change from baseline at Week 24 | 20.4 ± 17.0 |
| Change from baseline at Week 52 | 19.9 ± 19.1 |
| Change from baseline at Week 76 | 20.3 ± 19.5 |
CRT was measured in the study eye by spectral domain optical coherence tomography (SD-OCT).
| micrometer | Intravitreal (IVT) Aflibercept |
|---|---|
| Absolute CRT at baseline | 759.9 ± 246.0 |
| Absolute CRT at Week 24 | 271.2 ± 53.1 |
| Absolute CRT at Week 52 | 279.8 ± 106.8 |
| Absolute CRT at Week 76 | 265.4 ± 57.9 |
| Change from baseline at Week 24 | -488.9 ± 254.6 |
| Change from baseline at Week 52 | -481.3 ± 266.5 |
| Change from baseline at Week 76 | -496.1 ± 252.4 |
| injections | Intravitreal (IVT) Aflibercept |
|---|---|
| The Number of Injections Per Participant | 12.2 ± 2.53 |
The ETDRS chart includes 70 letters in total. More letters read correctly represents a better visual acuity
| percent | Intravitreal (IVT) Aflibercept |
|---|---|
| Week 24 | 68.8 ± 61.0 |
| Week 52 | 68.1 ± 60.3 |
The change in retinal non-perfusion status by fundus angiography (FA)/fundus photography (FP)-confirmed ischemic disc area. The status was categorized into: no non-perfusion, \<10 ischemic disc area, \>=10 ischemic disc area and missing status
| percent | Intravitreal (IVT) Aflibercept |
|---|---|
| Baseline to week 24: no to <10 | 4.4 |
| Baseline to week 24: no to >=10 | 3.8 |
| Baseline to week 24: no to missing | 6.3 |
| Baseline to week 24: <10 to no | 0.6 |
| Baseline to week 24: <10 to >=10 | 0.6 |
| Baseline to week 24: <10 to missing | 0 |
| Baseline to week 24: >=10 to no | 1.3 |
| Baseline to week 24: >=10 to <10 | 0 |
| Baseline to week 24: >=10 to missing | 0.6 |
| Baseline to week 24: missing to no | 0 |
| Baseline to week 24: missing to <10 | 0.6 |
| Baseline to week 24: missing to >=10 | 0.6 |
| Baseline to week 24: no status change | 81.9 |
| Baseline to week 52: no to <10 | 5.0 |
| Baseline to week 52: no to >=10 | 5.6 |
| Baseline to week 52: no to missing | 10.6 |
| Baseline to week 52: <10 to no | 1.9 |
| Baseline to week 52: <10 to >=10 | 0 |
| Baseline to week 52: <10 to missing | 0 |
| Baseline to week 52: >=10 to no | 1.9 |
| Baseline to week 52: >=10 to <10 | 0 |
| Baseline to week 52: >=10 to missing | 0 |
| Baseline to week 52: missing to no | 0 |
| Baseline to week 52: missing to <10 | 0.6 |
| Baseline to week 52: missing to >=10 | 0.6 |
| Baseline to week 52: no status change | 73.8 |
| Baseline to week 76: no to <10 | 3.1 |
| Baseline to week 76: no to >=10 | 4.4 |
| Baseline to week 76: no to missing | 18.1 |
| Baseline to week 76: <10 to no | 1.3 |
| Baseline to week 76: <10 to >=10 | 0.6 |
| Baseline to week 76: <10 to missing | 0.6 |
| Baseline to week 76: >=10 to no | 0.3 |
| Baseline to week 76: >=10 to <10 | 0 |
| Baseline to week 76: missing to no | 0 |
| Baseline to week 76: missing to <10 | 0.6 |
| Baseline to week 76: missing to >=10 | 0.6 |
| Baseline to week 76: no status change | 69.4 |
| percent | Intravitreal (IVT) Aflibercept |
|---|---|
| Baseline | 25.6 (19.1 to 33.1) |
| Week 24 | 98.7 (95.4 to 99.8) |
| Week 52 | 95.4 (90.8 to 98.1) |
| Week 76 | 97.8 (93.7 to 99.5) |
| Participants | Intravitreal (IVT) Aflibercept |
|---|---|
| Any ocular TEAEs | 90 |
| Severity: mild | 39 |
| Severity: moderate | 43 |
| Severity: severe | 8 |
Collected over Up to 30 days after week 76. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intravitreal (IVT) Aflibercept | 4/162 (2.5%) | 32/162 (19.8%) | 81/162 (50%) |
| Event | Intravitreal (IVT) Aflibercept |
|---|---|
| Atrial fibrillationCardiac disorders | 4/162 |
| Retinal ischaemiaEye disorders | 2/162 |
| Gastric ulcerGastrointestinal disorders | 2/162 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/162 |
| Atrial flutterCardiac disorders | 1/162 |
| Bundle branch block bilateralCardiac disorders | 1/162 |
| Cardiac failure acuteCardiac disorders | 1/162 |
| Mitral valve incompetenceCardiac disorders | 1/162 |
| Ventricular tachycardiaCardiac disorders | 1/162 |
| Amaurosis fugaxEye disorders | 1/162 |
| Event | Intravitreal (IVT) Aflibercept |
|---|---|
| Visual acuity reducedEye disorders | 26/162 |
| NasopharyngitisInfections and infestations | 26/162 |
| Intraocular pressure increasedInvestigations | 20/162 |
| HypertensionVascular disorders | 19/162 |
| Conjunctival haemorrhageEye disorders | 18/162 |
| Retinal haemorrhageEye disorders | 14/162 |
| Retinal ischaemiaEye disorders | 13/162 |
| Macular oedemaEye disorders | 12/162 |
| Vitreous detachmentEye disorders | 9/162 |
| Foreign body sensation in eyesEye disorders | 9/162 |
Safety analysis set: all participants who received any study drug
| Age, Continuous(years) | Intravitreal (IVT) Aflibercept |
|---|---|
| Mean | 66.4 ± 13.3 |
| Sex: Female, Male(Participants) | Intravitreal (IVT) Aflibercept |
|---|---|
| Female | 65 |
| Male | 97 |
| Ethnicity (NIH/OMB)(Participants) | Intravitreal (IVT) Aflibercept |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 156 |
| Unknown or Not Reported | 4 |
| Race (NIH/OMB)(Participants) | Intravitreal (IVT) Aflibercept |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 154 |
| More than one race | 0 |
| Unknown or Not Reported | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2016 to primary completion in Jul 2019, 37 months.
Results were first posted in Jul 2020, 11 months after primary completion.
Of 19 phase 4 interventional studies under Retinal Vein Occlusion, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 47. This study's 37 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept